Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

B Cell Maturation Antigen Targeted CAR-T Cells in Treatment With Relapsed and Refractory Multiple Myeloma

NCT05150522 is registered in ClinicalTrials.gov with Shenzhen University General Hospital as lead sponsor.

NCT NCT05150522
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05150522 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
B Cell Maturation Antigen Targeted CAR-T Cells in Treatment With Relapsed and Refractory Multiple Myeloma
Lead sponsor
Shenzhen University General Hospital
Phase
Phase 1/2
Overall status
Unknown status
Start date
July 1, 2021
Completion date
July 31, 2024
Enrollment
10 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma, refractory multiple myeloma, relapse multiple myeloma